

Fast Screening Tool Rates Patients' Health Literacy

BY BRUCE JANCIN
Denver Bureau

PHOENIX — Three brief screening questions enable physicians to spot patients lacking the literacy skills necessary to understand and act upon health care information, Lorraine S. Wallace, Ph.D., said at a congress sponsored by the Association for Academic Surgery and the Society of University Surgeons.

"Surgeons should consider administering these three screening items to identify patients at increased risk of having limited health literacy skills. Our results pretty much echo what other researchers have found regarding the three questions in primary care settings," said Dr. Wallace of the department of family medicine at the University of Tennessee, Knoxville.

According to the Institute of Medicine's landmark 2004 report, "Health Literacy: A Prescription to End Confusion," nearly 50% of English-speaking adults lack the literacy skills needed to adequately use the health care system. The consequences include delayed diagnoses, poor adherence to medical advice, less use of preventive services, deficient self-management skills, more hospitalizations, and worse short- and long-term health outcomes. By one estimate, the price tag for poor health literacy adds up to \$69 billion per year.

Moreover, last year the Editorial Projects in Education Research Center, supported by the Bill and Melinda Gates Foundation, reported that fully 30% of U.S. ninth graders fail to finish high school with a diploma.

Dr. Wallace noted that more than 800 published studies demonstrate that patient education materials are far too difficult for the average patient to understand. The great majority of this research has been done in primary care settings and has relied upon assessment tools too cumbersome for use in clinical practice.

Despite this large body of evidence, however, limited health literacy "still isn't even on residents' radar screens" at most academic medical centers, Dr. Wallace said. "The first issue for physician educators is to get them to understand that the high school dropout rate across America is 29%. That's who your patient population is."

Dr. Wallace sought to determine whether the screening questions for limited health literacy previously studied in primary care are also accurate in the surgical setting.

The questions were as follows:

- ▶ How often do you have someone (like a family member, friend, or hospital worker) help you read hospital materials?
- ▶ How confident are you filling out medical forms by yourself?
- ▶ How often do you have problems learning about your medical condition because of difficulty understanding written information?

Patients rate their answers to each question on a 1-5 scale.

Dr. Wallace studied 100 adult patients attending a vascular surgery clinic for an initial consultation. None had overt psychiatric illness or severe cognitive impairment. They averaged 62 years of age; 65 were women and 96 were Caucasian, re-

flecting east Tennessee demographics. Also, 32 hadn't completed high school.

All participants were assessed according to the Rapid Estimate of Adult Literacy in Medicine (REALM), which is considered the accepted standard for evaluating patient literacy skills; 39 patients scored in the limited or marginal health literacy range.

The area under the receiver operating characteristic curves for each of the three screening questions using REALM scores as the reference standard was 0.83-0.86.

That's a favorable result. It indicates these specific questions are effective in identifying patients at greatest risk of limited health literacy.

"These questions are nonthreatening. It's not like asking, 'Can you read?' Studies have shown that patients with limited literacy skills do indeed harbor a tremendous amount of shame. It's information they're not about to offer to anyone, let alone their physician," Dr. Wallace explained.

The audience pressed Dr. Wallace as to

what exactly she does differently when the screening questions identify a patient with a problem. She replied that while it's clear the clinical interaction has to be tailored accordingly, "there's not really any hard evidence to date as to what will work, unfortunately."

She and her coinvestigators hope to change that. The study she presented is a part of a larger ongoing patient/surgeon communication project aimed at providing specific physician guidance. ■

PROVIGIL
(MODAFINIL)
Tablets

Cephalon
deliver more™

© 2007 Cephalon, Inc. All rights reserved.
PRO885 Mar 2007 Printed in USA.

Cut through the fog of excessive sleepiness (ES) with PROVIGIL



Help your patients with obstructive sleep apnea (OSA) escape the fog of ES with PROVIGIL

- PROVIGIL is a nonamphetamine wake-promoting agent
- PROVIGIL helps patients with ES associated with OSA stay awake and alert
- PROVIGIL significantly improves clinical condition
- PROVIGIL does not affect a patient's ability to sleep when sleep is desired
- PROVIGIL exhibits a favorable safety profile

PROVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS), and shift work sleep disorder (SWSD).

In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction.

Important Information for Physicians

Patients with abnormal levels of sleepiness who take PROVIGIL should be advised that their level of wakefulness may not return to normal. Patients with excessive sleepiness, including those taking PROVIGIL, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.

PROVIGIL is listed in Schedule IV of the Controlled Substances Act.

PROVIGIL produces psychoactive and euphoric effects, alterations in mood, perception, thinking and feelings typical of other CNS stimulants. Physicians should follow patients closely, especially those with a history of drug and/or stimulant (eg, methylphenidate, amphetamine, or cocaine) abuse. Patients should be observed for signs of misuse or abuse (eg, incrementation of doses or drug-seeking behavior).

In clinical trials, PROVIGIL was generally well tolerated. The most frequently reported adverse events (≥5%) were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia. Most adverse events were mild to moderate. PROVIGIL may interact with drugs that inhibit, induce, or are metabolized by cytochrome P450 isoenzymes.

Please see brief summary of full prescribing information for PROVIGIL on adjacent page.

For more information, visit www.PROVIGIL.com or call 1-800-896-5855.